New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareAOD-9604 vs MGF (Mechano Growth Factor)

AOD-9604 vs MGF (Mechano Growth Factor)

Side-by-side comparison of key properties, dosing, and research.

Fat Loss & Metabolic
AOD-9604
Anabolic & IGF
MGF (Mechano Growth Factor)
Summary
AOD-9604 is a modified fragment of human growth hormone (residues 177-191) with an additional tyrosine residue that significantly enhances bioavailability. Originally developed as an anti-obesity drug by Metabolic Pharmaceuticals, it stimulates lipolysis and inhibits lipogenesis without the diabetogenic effects of full GH.
MGF (Mechano Growth Factor) is a splice variant of IGF-1 that is locally produced in muscle tissue in response to mechanical damage from exercise. It activates muscle satellite cells (stem cells) to proliferate and repair damaged fibers, making it specifically targeted at exercise-induced hypertrophy.
Half-Life
30-45 minutes injectable; longer with nasal spray formulation
Native MGF: minutes. PEG-MGF: ~3 days
Admin Route
SubQ, Intranasal, Oral
SubQ, IM
Research
Typical Dose
300-600 mcg
200–400 mcg
Frequency
Once daily
1–2 times per week
Key Benefits
  • Selective fat loss without anabolic side effects
  • No effect on blood glucose or insulin resistance
  • Improved bioavailability over Fragment 176-191
  • GRAS (Generally Recognized As Safe) status in Australia
  • Potential cartilage repair and anti-inflammatory properties
  • Does not suppress natural GH production
  • Activates muscle satellite cells for repair and growth
  • Accelerates recovery from muscle damage
  • Synergistic with IGF-1 LR3 (different mechanisms)
  • Promotes muscle hypertrophy specifically at exercised muscles
  • Faster recovery between training sessions
  • Potential for injury repair in connective tissue
Side Effects
  • Localized injection site reactions
  • Headache (rare)
  • Hypoglycemia risk in combination with insulin (very rare)
  • Muscle soreness (satellite cell activation)
  • Injection site irritation
  • Hypoglycemia risk (modest, less than IGF-1 LR3)
Stacks With